7 GLP-1 Programs I’d Actually Tell a First-Timer to Try in 2026

My neighbor knocked on my door last spring holding a printed-out list of telehealth sites, overwhelmed and honestly a little embarrassed. She’d been quoted $1,400 a month at one place, turned away at another because her insurance didn’t qualify, and scared off a third time by a website that refused to name its pharmacy. She just wanted to know: which one is actually worth starting with?

That question is what this list is for.

1. HealthRX

Verdict: Best overall starting point for cash-pay GLP-1 beginners.

Here’s what made me put HealthRX first. The entry price on compounded semaglutide is genuinely low, around $99 a month, without requiring a membership layer, an insurance fight, or a coaching package you didn’t ask for. Compounded tirzepatide runs around $149. Those numbers are hard to beat among legitimate, physician-reviewed telehealth options.

But price alone wouldn’t earn the top slot. What matters more for a nervous first-timer is knowing who’s actually touching your medication. HealthRX dispenses through Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy that operates under USP-797 standards with lot-to-door tracking on every shipment. That’s a named facility with a physical address, not a vague “partnered pharmacy” line. The program also carries LegitScript certification (certificate number 50087439), which is an independent credential, not self-awarded.

The workflow is straightforward. You fill out a health assessment online, a board-certified U.S. physician reviews it within about 24 hours, and if you’re approved, medication ships overnight, free, to all 50 states. No contracts. No hidden fees.

The cited efficacy figures HealthRX references come from published clinical trials, not from its own patient data. SURMOUNT-1 showed tirzepatide averaging around 21% body weight reduction at 72 weeks. The STEP 1 trial showed semaglutide averaging around 15% at 68 weeks. These are compounded medications, not FDA-approved branded drugs, so results will vary and the compounds are not interchangeable with brand-name products.

For someone starting from zero with a cash budget, this is where I’d point them first.

2. Mochi Health

Verdict: Strongest clinical oversight at a price that’s still accessible.

Mochi connects patients with board-certified obesity-medicine physicians, not just general practitioners approving refills. Monthly costs come in at roughly $99 for compounded semaglutide and about $199 for tirzepatide. The monitoring is more involved than most budget options, which is worth it if you have metabolic complexity or want regular check-ins baked into the model.

3. FormBlends

Verdict: Right pick if you want published lab data or a broader peptide catalog alongside your GLP-1.

FormBlends occupies a specific niche: it publishes per-product purity testing with actual numbers, including HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results. Most GLP-1 telehealth brands tell you their pharmacy is “high quality” and stop there. FormBlends shows the data. That transparency matters to some buyers.

It also carries a wider catalog of peptides, recovery compounds, and longevity-oriented options under the same clinician model, which is unusual. If you’re interested in GLP-1 therapy alongside, say, peptide-based recovery support, this is the one brand where that’s possible from a single provider.

The trade-off is price. Semaglutide runs around $299 and tirzepatide around $349 per vial, meaningfully higher than HealthRX’s entry pricing. Shipping covers 47 states, not all 50. So HealthRX wins on access and cost for most beginners, but FormBlends earns its spot for the subset of buyers who want to see the lab work or want expanded options beyond GLP-1s alone.

*Quick honest note here: I’m not a doctor, none of this is medical advice, and compounded GLP-1 medications are not FDA-approved products regardless of which telehealth brand you choose.*

4. Henry Meds

Verdict: Fast turnaround for cash-pay patients who want to skip insurance entirely.

Henry Meds focuses on cash-pay compounded GLP-1s with shipping that typically hits 24 to 72 hours after approval. First-month pricing lands around $179 to $249. The monitoring is lighter than Mochi’s, which suits people who mainly want access to the medication without a heavy coaching structure.

5. Ro Body

Verdict: Best infrastructure for patients who want to try insurance first.

Ro’s first month runs around $39, then steps up to roughly $74 to $149 monthly, with medications billed separately. The prior-authorization team is a real differentiator. Ro will actually work the insurance approval process for branded medications on your behalf. If you have coverage and want to pursue Wegovy or a branded option before defaulting to compounded, Ro is built for that path.

6. Hims & Hers

Verdict: Familiar brand, now focused on branded meds after March 2026.

Following the March 2026 Novo Nordisk settlement, Hims & Hers shifted away from compounded GLP-1s and toward branded medications. Injectable Wegovy runs around $299 a month through the platform, oral options around $249, and Zepbound around $399. With insurance plus a savings card, some patients get down to nearly nothing per month. The brand is polished and the app experience is smooth. Not the cheapest cash-pay option, but a reasonable choice for insured patients.

7. PlushCare

Verdict: Good fit for patients who already have a PCP relationship and want same-day availability.

PlushCare charges around $19.99 a month for membership, works with insurance for branded meds, and offers same-day appointment slots. It functions more like a primary care telehealth practice that also handles GLP-1 prescriptions, so the clinical interaction feels less transactional than some weight-loss-specific platforms.

Final Thought

Starting a GLP-1 program is less complicated than it looked a year ago, but the number of providers has made comparison genuinely hard. For most cash-pay beginners, HealthRX clears the most important bars: low price, named pharmacy, fast physician review, and free nationwide overnight shipping. Everyone else on this list earns their spot for a specific type of buyer, whether that’s lab transparency, insurance navigation, or clinical depth.

Common Questions

Is a compounded GLP-1 from HealthRX or Mochi the same drug as Wegovy or Zepbound?

No. Compounded semaglutide and tirzepatide are copies made by 503A pharmacies, not the FDA-approved branded products. The active molecule is intended to be identical, but compounded versions skip the FDA’s drug-approval process. Clinical trial results cited by these programs come from branded-drug studies, not from compounded versions specifically.

If Hims & Hers stopped offering compounded GLP-1s after March 2026, what does that mean for people mid-program?

It means the platform now routes patients toward branded Wegovy, Zepbound, or oral options instead of lower-cost compounded versions. Patients already on a compounded regimen through Hims & Hers before the settlement would have needed to transition. Anyone starting fresh in 2026 will be quoted branded-drug pricing, which is why cash-pay beginners often look elsewhere first.

Which of these programs actually requires the least paperwork to get started?

HealthRX and Henry Meds are the lightest on friction. Both use an online health assessment rather than a live appointment, and physician review runs around 24 hours or less. Ro Body involves more back-and-forth if you want insurance billing. PlushCare requires scheduling a same-day appointment, which adds a step even if it’s quick.

Does Mochi Health’s obesity-medicine focus actually change what you get compared to a general telehealth prescriber?

Practically, yes. Obesity-medicine board certification means the physician has specific training in metabolic disease, not just authority to write a prescription. For patients with thyroid conditions, prior bariatric surgery, or Type 2 diabetes already being managed, that specialty background can shape dosing decisions and monitoring in ways a general practitioner may not prioritize.

Can FormBlends’ published purity data be independently verified, or is it self-reported?

FormBlends publishes HPLC purity percentages, mass spec identity results, and endotoxin sterility numbers per product. Whether a given buyer can independently verify those numbers depends on whether the reports name the testing lab and include batch identifiers. The data being published at all puts FormBlends ahead of most competitors, but reading the actual certificates of analysis before ordering is still worth doing.

Sources

• FDA warning letters to compounding telehealth firms, early 2026 (FDA.gov official communications)
• Novo Nordisk settlement announcement, March 9 2026 (Reuters, STAT News coverage)
• SURMOUNT-1 tirzepatide trial, New England Journal of Medicine, 2022
• STEP 1 semaglutide trial, New England Journal of Medicine, 2021
• LegitScript certification database (LegitScript.com, public search)
• USP-797 pharmaceutical compounding standards (USP.org)
• Lilly orforglipron LillyDirect pricing, reported April 2026 (STAT News, Bloomberg Health)